QuilliChew ER is Used for ADHD Treatment
QuilliChew ER (methylphenidate hydrochloride extended-release chewable tablets) is a central nervous system stimulant indicated specifically for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in patients 6 years of age and older 1.
Key Clinical Information
Primary Indication
QuilliChew ER helps increase attention and decrease impulsiveness and hyperactivity in people with ADHD 1. It is an extended-release chewable formulation designed to be chewed before swallowing, providing once-daily dosing convenience 2.
Important Clarification
QuilliChew ER contains methylphenidate, NOT nicotine. The question appears to conflate QuilliChew with nicotine products, but these are entirely different substances. QuilliChew ER is a Schedule II controlled substance due to its methylphenidate content, which has high potential for abuse and dependence 1.
Critical Safety Considerations
Contraindications
- Do not use if allergic to methylphenidate hydrochloride
- Do not use if taking or have taken MAOIs within the past 14 days 1
High-Risk Populations Requiring Careful Evaluation
- Patients with heart defects or serious heart disease (sudden death has occurred) 1
- History of mental health problems (psychosis, mania, bipolar illness, depression)
- History of substance abuse or dependence
- Patients with phenylketonuria (PKU) - QuilliChew ER contains phenylalanine as part of aspartame 1
Monitoring Requirements
- Blood pressure and heart rate should be checked regularly during treatment
- Screen for abuse, misuse, and addiction risk before starting and monitor throughout treatment 1
- Watch for new or worsening psychiatric symptoms (hallucinations, delusions, mania, aggression)
Age Restrictions
Safety and efficacy have not been established in children under 6 years of age 1.